ClinicalTrials.gg

Program

feladilimab

Also written as “Feladilimab” and “feladilimab (GSK3359609)”.

Its studies are mostly in Neoplasms · Multiple Myeloma · Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of Head and Neck · Head and Neck Neoplasms, led by GlaxoSmithKline.

Furthest: phase 3, since Oct 15, 20198 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline81 open or runningphase 3since Oct 15, 2019Mar 24, 2016none ahead

Also a collaborator on its studies: iteos-belgium-sa, Merck and AstraZeneca.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 24, 2016First study: phase 1 study in NeoplasmsFirst studyNCT02723955 · 829 enrolled · United States, Australia, Canada and more
  2. Oct 1, 2018Phase 2 study in NeoplasmsNCT03693612 · 26 enrolled · United States, Australia, Canada
  3. Nov 9, 2018Phase 2 study in NeoplasmsNCT03739710 · 175 enrolled · United States, Canada, France and more
  4. Oct 15, 2019Phase 3 study in Head and Neck NeoplasmsNCT04128696 · 315 enrolled · United States, Argentina, Australia and more
  5. Jun 9, 2020Phase 3 study in Head and Neck NeoplasmsNCT04428333 · 117 enrolled · United States, Argentina, Australia and more
  6. Sep 21, 2022Phase 2 study in NeoplasmsNCT05553808 · 105 enrolled · United States, Canada, France and more
  7. Jan 22, 2025Phase 2 study in NeoplasmsNCT06790303 · 8 enrolled · United States, Canada, France
  8. Oct 13, 2025Phase 2 study in Multiple MyelomaNCT07217119 · 25 enrolled · United States, Australia, Canada and more

TargetBeta

ICOS →read by rule
“Inducible T-cell costimulator agonist”ChEMBL 37, by rule

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07217119Multiple Myeloma · United States, Australia, Canada and more2Active, not recruitingApr 17, 202525
NCT06790303Neoplasms · United States, Canada, France2TerminatedSep 23, 20218
NCT05553808Neoplasms · United States, Canada, France and more2CompletedSep 23, 2021105
NCT04428333Head and Neck Neoplasms · United States, Argentina, Australia and more3TerminatedApr 27, 2021117
NCT04128696Head and Neck Neoplasms · United States, Argentina, Australia and more3TerminatedApr 27, 2021315
NCT03739710Neoplasms · United States, Canada, France and more2CompletedMay 2, 2024175
NCT03693612Neoplasms · United States, Australia, Canada2CompletedJun 25, 202126
NCT02723955Neoplasms · United States, Australia, Canada and more1CompletedJul 5, 2023829

How it is read

Names in the registry

  • “Feladilimab”, 5 entries
  • “feladilimab”, 2 entries
  • “feladilimab (GSK3359609)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.